Roivant's mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity.
Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch "Vants" - nimble and focused biopharmaceutical and health technology companies.
Immunovant
Enabling normal lives for patients with autoimmune diseases
Dermavant
Leading innovation in medical dermatology
Genevant
Delivering results through RNA therapeutics
Proteovant
Degrading errant proteins to elevate patient health
Kinevant
Developing a new therapy for sarcoidosis
Hemavant
Exploring novel solutions for blood disorders
Lysovant
Developing a novel endolysin for bacterial infections
Affivant
Developing bispecific antibodies for solid tumors
Aruvant
Developing gene therapies for rare diseases
Lokavant
Shifting the paradigm in clinical trial intelligence
Vant.AI
Expanding the boundaries of in-silico drug design
Datavant
Organizing the world's healthcare data
Cytovant
Developing novel and innovative cellular therapeutics in Asia
Roivant Health is our platform for founding and funding innovative digital health businesses.
As an integrated pharma-tech business, we hope to lead the transition to a more data-driven, patient-centric, and value-oriented health system. Companies we have built include Datavant, now the nation's largest health data ecosystem, and Lokavant, a leading clinical trial intelligence company creating operational transparency for sponsors and CROs.
Partners
We have a diverse pipeline of investigational drugs across our family of companies.
Roivant empowers a global team of innovators in the biopharmaceutical industry to expand the world of treatable conditions.
With offices in New York City, Boston, and Basel as well as remote working options, collaborating on a better future together has never been easier.
Matt Gline
Chief Executive Officer
Eric Venker, MD
President & Chief Operating Officer
Mayukh Sukhatme
President & Chief Investment Officer
Frank Torti, MD
Vant Chair
Srini Ramanathan, PhD
Chief Development Officer
Richard Pulik
Chief Financial Officer
Rakhi Kumar
Chief Accounting Officer
Jo Chen
General Counsel
Woody Sherman, PhD
Chief Computational Scientist
Alex Gasner
EVP, Roivant Health
Matt Maisak
Chief Operating Officer, Roivant Platforms
Pete Salzmann, MD, MBA
CEO, Immunovant
Todd Zavodnick
CEO, Dermavant
Bill Gerhart
CEO, Kinevant
William Chou, MD
CEO, Aruvant
Pete Lutwyche
CEO, Genevant
Drew Fromkin
CEO, Proteovant
Lindsay Androski
CEO, Roivant Social Ventures
Benjamin Zimmer
CEO, Priovant
Rohit Nambisan
CEO, Lokavant
John Xu, MD
President, Cytovant
Bill Macias, MD, PhD
Chief Medical Officer, Immunovant
Chris Chapman
Chief Commercial Officer, Dermavant
Chris Van Tuyl
Chief Legal Officer, Dermavant
Christopher Winter, PhD
Head of Portfolio Strategy, Roivant Discovery
David Rubenstein, MD, PhD
Chief Scientific Officer, Dermavant
Huafeng Xu, PhD
CTO, Roivant Discovery
James Heyes, PhD
Chief Scientific Officer, Genevant
John Alfano
Chief Operating Officer, Lokavant
Julia G. Butchko
Chief Development & Technology Officer, Immunovant
Michael Swartzburg
Chief Financial Officer, Dermavant
Pamela Carroll, PhD
Chief Business Officer, Roivant Discovery
Paul Seaback
Chief Technical Officer, Dermavant
Pete Zorn
Chief Legal Officer, Genevant
Philip Brown, MD, JD
Chief Medical Officer, Dermavant
Matt Gline
Chief Executive Officer
Vivek Ramaswamy
Chairman
Andrew Lo
Director
Patrick Machado
Director
Ilan Oren
Director
Daniel Gold
Director
Masayo Tada
Director
James C. Momtazee
Director
Keith Manchester
Director
Roivant's drug discovery capabilities are driven by our industry-leading computational platform, which combines preeminent physics-based simulation tools with machine learning to generate unprecedented predictive power that can tackle previously intractable challenges.
The tight integration of our computational platform with our broad experimental capabilities and deep drug discovery experience enables the rapid design and optimization of new drugs to address a wide range of targets for diseases with high unmet need.
NEW YORK
Roivant Sciences, Inc.
151 W 42nd Street
15th Floor
New York, NY 10036
United States
BOSTON
Roivant Sciences, Inc.
451 D Street
Boston, MA 02210
United States
BASEL
Roivant Sciences GmbH
Viaduktstrasse 8
4051 Basel
Switzerland